|
|
|
|
|
|
|
|
|
23.01.26 - 22:18
|
Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026 (GlobeNewswire EN)
|
|
|
BASEL, Switzerland and LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 6, 2026, to report its financial results for the second quarter ended December 31, 2026, and provide a business update....
|
|
|
|
|
13.01.26 - 14:03
|
Proxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicines (Business Wire)
|
|
|
NEW YORK & BOSTON--(BUSINESS WIRE)--#AI--Proxima (formerly VantAI), the AI-native biotech company pioneering the next generation of AI-driven drug discovery for proximity therapeutics, today announced an oversubscribed $80M seed financing. The round was led by DCVC, with participation from NVentures (NVIDIA's venture capital arm), Braidwell, Roivant, AIX Ventures, Yosemite, Magnetic Ventures, Alexandria Venture Investments, Modi Ventures, and additional strategic and institutional investors.
As part of the financing, the company has rebranded from VantAI to Proxima to reflect its singular focus on building out both the technology and data layer needed to unlock proximity-based therapeutics. These next generation medicines work by controlling how proteins interact with one another, rather than simply inhibiting or activating a single target, and represent a superset that includes modalities such as molecular glues and PROTACs that have the potential to unlock historically undruggable disease targets.
The ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
